[ad_1]
MOSCOW, April 3. / TASS /. Assessment of the level of immunity formed after vaccination with the Epivakkoron coronavirus vaccine should be carried out by special ELISA tests. This is due to the fact that the vaccine induces antibodies against precisely those parts of the coronavirus protein that are functionally important in its life cycle, according to the agency’s website.
“For vaccination with peptide antigens, a smaller range of antibodies is characteristic. The Epivaccoron peptide vaccine induces antibodies against precisely those regions of the novel coronavirus S-envelope protein that are functionally important in the life cycle of the virus. <...> In this regard, to assess the level formed after the introduction of the immunity vaccine, it is necessary to use special “SARS-CoV-2-IgG-Vector” ELISA test systems, the ministry said.
It is emphasized that the sensitivity of most tests may be insufficient to detect a small group of key antibodies formed after inoculation with Epivaccorone, as most commercial test kits are intended to detect a wide range of antibodies against different regions of the virus envelope protein S. “These test systems with a high probability will not detect antibodies in people vaccinated with Epivakvorone,” says the report, which also indicates that ELISA tests are supplied to all regions of the Russian Federation, where the population is vaccinated with the vaccine. Epivakkoron.
